-
Views
-
Cite
Cite
Amar Safdar, M. Alma Rodriguez, Luis E. Fayad, Gilhen H. Rodriguez, Barbara Pro, Michael Wang, Jorge E. Romaguera, Andre H. Goy, Fredrick B. Hagemeister, Peter McLaughlin, Gerald P. Bodey, Larry W. Kwak, Issam I. Raad, Robert B. Couch, Dose-Related Safety and Immunogenicity of Baculovirus-Expressed Trivalent Influenza Vaccine: A Double-Blind, Controlled Trial in Adult Patients with Non-Hodgkin B Cell Lymphoma, The Journal of Infectious Diseases, Volume 194, Issue 10, 15 November 2006, Pages 1394–1397, https://doi.org/10.1086/508493
- Share Icon Share
Abstract
In 27 patients randomized to receive commercial trivalent influenza vaccine (TIV) containing 15 μg of the hemagglutinin (HA) of influenza A (H3N2 and H1N1) and B virus or a recombinant vaccine (rHAO) containing 15, 45, or 135 μg of each HA, reactogenicity was minor. Among patients with similar prevaccination titers, 40% given 45 μg and 60% given 135 μg of rHAO developed an increase in influenza A/H3 neutralizing antibody levels; there were no increases in 4 given TIV. For each vaccine, the highest frequencies of increases in neutralizing antibody levels and the highest mean titers occurred in those given the 135-μg vaccine